WO1993016180A2 - Sequences genetiques pour un antigene 90k associe aux tumeurs (ir-95) - Google Patents

Sequences genetiques pour un antigene 90k associe aux tumeurs (ir-95) Download PDF

Info

Publication number
WO1993016180A2
WO1993016180A2 PCT/EP1993/000382 EP9300382W WO9316180A2 WO 1993016180 A2 WO1993016180 A2 WO 1993016180A2 EP 9300382 W EP9300382 W EP 9300382W WO 9316180 A2 WO9316180 A2 WO 9316180A2
Authority
WO
WIPO (PCT)
Prior art keywords
sep
antigen
leu
ala
gly
Prior art date
Application number
PCT/EP1993/000382
Other languages
English (en)
Other versions
WO1993016180A3 (fr
WO1993016180A1 (fr
Inventor
Axel Ullrich
Irmingard Sures
Mohammad Azam
Stefano Iacobelli
Clara Natoli
Original Assignee
Max Planck Gesellschaft
Uni Degli Studi G D Annunzio C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Max Planck Gesellschaft, Uni Degli Studi G D Annunzio C filed Critical Max Planck Gesellschaft
Publication of WO1993016180A2 publication Critical patent/WO1993016180A2/fr
Publication of WO1993016180A1 publication Critical patent/WO1993016180A1/fr
Publication of WO1993016180A3 publication Critical patent/WO1993016180A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Antigène 90K associé aux tumeurs et sensiblement purifié, ou un ou plusieurs fragments de celui-ci. Il est obtenu notamment à partir du liquide de culture de la lignée cellulaire CG-5 du cancer du sein chez la femme; du sérum d'une personne atteinte du cancer ovarien. L'antigène natif a un poids moléculaire de 95 000 daltons environ et il est présent sous la forme d'un complexe à poids moléculaire élevé. On a prévu la purification et la caractérisation de l'antigène, ainsi que ses utilisations. On a également prévu des séquences nucléotidiques codant l'antigène 90K, ou un ou plusieurs fragments de celui-ci, des véhicules contenant la séquence génétique, des hôtes transformés à l'adie de ceux-ci, ainsi que la production de l'antigène, ou de ses fragments, à l'aide de l'hôte transformé.
PCT/EP1993/000382 1992-02-17 1993-02-17 Sequences genetiques pour un antigene 90k associe aux tumeurs (ir-95) WO1993016180A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM92A000100 1992-02-17
ITRM920100A IT1254309B (it) 1992-02-17 1992-02-17 Sequenze genetiche per l'antigene 90k associato a tumori.

Publications (3)

Publication Number Publication Date
WO1993016180A2 true WO1993016180A2 (fr) 1993-08-19
WO1993016180A1 WO1993016180A1 (fr) 1993-08-19
WO1993016180A3 WO1993016180A3 (fr) 1993-09-30

Family

ID=

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012681A1 (fr) * 1993-11-05 1995-05-11 New York University Procede relatif a l'ir-95
WO2001051515A2 (fr) * 2000-01-10 2001-07-19 Chiron Corporation Genes exprimes de maniere differentielle dans le cancer du sein
WO2001057207A2 (fr) * 2000-02-04 2001-08-09 Corixa Corporation Compositions et methodes destinees a la therapie et au diagnostic du cancer de l'ovaire
US7081517B2 (en) 2000-01-10 2006-07-25 Chiron Corporation Genes differentially expressed in breast cancer
WO2010097825A1 (fr) * 2009-02-25 2010-09-02 Stefano Iacobelli Utilisation d'anticorps monoclonaux anti-90k pour la prévention et le traitement de tumeurs et des métastases de celles-ci
WO2020099235A1 (fr) 2018-11-12 2020-05-22 Mediapharma S.R.L. Anticorps bispécifiques dirigés contre 90k humain, et soit l'endosialine, soit her3

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995012681A1 (fr) * 1993-11-05 1995-05-11 New York University Procede relatif a l'ir-95
WO2001051515A2 (fr) * 2000-01-10 2001-07-19 Chiron Corporation Genes exprimes de maniere differentielle dans le cancer du sein
WO2001051515A3 (fr) * 2000-01-10 2002-01-24 Chiron Corp Genes exprimes de maniere differentielle dans le cancer du sein
US7081517B2 (en) 2000-01-10 2006-07-25 Chiron Corporation Genes differentially expressed in breast cancer
EP1985701A3 (fr) * 2000-01-10 2009-01-07 Novartis Vaccines and Diagnostics, Inc. Gène s'exprimant par action différentielle dans le cancer du sein
US7605246B2 (en) 2000-01-10 2009-10-20 Novartis Vaccines And Diagnostics, Inc. Genes differentially expressed in breast cancer
US8236928B2 (en) 2000-01-10 2012-08-07 Novartis Vaccines And Diagnostics, Inc. Genes differentially expressed in breast cancer
WO2001057207A2 (fr) * 2000-02-04 2001-08-09 Corixa Corporation Compositions et methodes destinees a la therapie et au diagnostic du cancer de l'ovaire
WO2001057207A3 (fr) * 2000-02-04 2002-07-04 Corixa Corp Compositions et methodes destinees a la therapie et au diagnostic du cancer de l'ovaire
WO2010097825A1 (fr) * 2009-02-25 2010-09-02 Stefano Iacobelli Utilisation d'anticorps monoclonaux anti-90k pour la prévention et le traitement de tumeurs et des métastases de celles-ci
US8679495B2 (en) 2009-02-25 2014-03-25 Mediapharma S.R.L. Use of anti-90K monoclonal antibodies for the prevention and treatment of tumors and metastases thereof
WO2020099235A1 (fr) 2018-11-12 2020-05-22 Mediapharma S.R.L. Anticorps bispécifiques dirigés contre 90k humain, et soit l'endosialine, soit her3

Also Published As

Publication number Publication date
ITRM920100A0 (it) 1992-02-17
ZA931101B (en) 1994-08-17
ITRM920100A1 (it) 1993-08-17
WO1993016180A3 (fr) 1993-09-30
AU3497893A (en) 1993-09-03
CN1076489A (zh) 1993-09-22
IT1254309B (it) 1995-09-14

Similar Documents

Publication Publication Date Title
O’Brien et al. The CA 125 gene: an extracellular superstructure dominated by repeat sequences
EP0683234B2 (fr) Anticorps dirige contre le beta-amyloide ou un derive de ce dernier et son utilisation
JP3799483B2 (ja) ガン関連抗原をコードする単離核酸分子、その抗原、およびそれらの利用方法
Khamlichi et al. Purification and partial characterization of the erythrocyte Kx protein deficient in McLeod patients
EP0442926A1 (fr) Polypeptides
CN100378121C (zh) 分离的结合mhcⅰ类和mhcⅱ类分子的同ny－eso－1的氨基酸序列相关的肽及其应用
Sachiho et al. The gene encoding mouse lymphocyte antigen Ly-49: structural analysis and the 5'-flanking sequence
JPH0675514B2 (ja) ヒト非小細胞肺癌に関するモノクローナル抗体
WO1996013581A1 (fr) Peptide empechant la croissance et procedes d'utilisation de ce peptide
US7385044B2 (en) Isolated peptides which bind to MHC Class II molecules, and uses thereof
US5942404A (en) Cell surface protein expressed on human cortical thymocyte and their use
WO1993016181A1 (fr) Antigene 90k associe aux tumeurs (ir-95)
KR100382628B1 (ko) 인터페론α/β결합단백질과이의제조및용도
Brandt et al. Functional and molecular characterization of a monoclonal antibody against human interleukin 2
WO1993016180A2 (fr) Sequences genetiques pour un antigene 90k associe aux tumeurs (ir-95)
WO1993016180A1 (fr) Sequences genetiques pour un antigene 90k associe aux tumeurs (ir-95)
Puré et al. Properties of a second epitope of the murine Fc receptor for aggregated IgG.
EP0265847B1 (fr) Anticorps monoclonal réagissant avec le TRF (interleukine 5)
Tsujisaki et al. Preparation and characterization of monoclonal antibodies specific to synthetic peptide of carcinoembryonic antigen
Salmi et al. A mouse molecular mimic of human vascular adhesion protein-1
JPH03502446A (ja) 動物およびヒトのレクチン類の少なくとも一部分の配列を再現するアミノ酸配列，それを得る方法，およびその診断および治療への用途
JPH07203961A (ja) 新規なメタロプロテアーゼおよびそれをコードするｄｎａ
Tokuyama et al. Separation and comparison of human TL-like antigens and HLA (A, B, C) antigens expressed on cultured T cells
US20060269960A1 (en) Isolated peptides corresponding to amino acid requirements of NY-ESO-1, which bind to MHC Class I and MHC Class II molecules, and uses thereof
Prohaska et al. Characterization of the human erythrocyte complement receptor CR1 (C3b receptor) by epitope mapping

Legal Events

Date Code Title Description
CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: PAT.BUL.20/93 UNDER PUBLISHED REPLACE "A1" BY "A2"

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

EX32 Extension under rule 32 effected after completion of technical preparation for international publication

Free format text: KZ

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)

Free format text: PL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)

Free format text: PL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)

Free format text: PL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)

Free format text: PL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)

Free format text: PL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)

Free format text: PL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)

Free format text: PL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA